Newsletter · · Ashutosh Agarwal

Lilly and Novo Obesity War Goes to Court as Biotech Comeback Builds - Weekly Pharma Biotech Podcast Recap - Week of July 26, 2026

Weekly Pharma / Biotech / Life Sciences Podcast Recap for the week of July 19 to 26, 2026. Novo Nordisk sued Eli Lilly over obesity-drug advertising as Lilly extended its lead, a genuine biotech comeback mood built across the finance shows, life-science tools stocks led by Danaher had a rough week, and gene editing, AI drug discovery, and ASCO cancer data drew deals and debate.

Weekly Pharma / Biotech / Life Sciences Podcast Recap

Week of July 26, 2026: Lilly and Novo Obesity War Goes to Court as Biotech Comeback Builds

This week's podcasts were dominated by one story above all others: the obesity-drug war between Eli Lilly and Novo Nordisk turned openly hostile, with Novo suing Lilly over its advertising. Underneath that headline, three quieter but important threads ran through the week, a genuine "biotech is back" mood on the finance shows, a bad day for the companies that supply the drug industry (led by Danaher), and a steady drumbeat of deals and data in gene editing, AI drug discovery, and cancer. Below is what the shows actually said, with the numbers, names, and quotes worth keeping.

1. Dominant Themes

Theme 1: The Lilly vs. Novo obesity war goes to court. The single most-covered event of the week was Novo Nordisk filing a lawsuit against Eli Lilly over how Lilly advertises its weight-loss drug Zepbound against Novo's Wegovy. The dispute is about the math in the ads. Lilly's ads compare its drug to an older, lower dose of Wegovy (2.4 mg), while Novo argues the fair comparison is its newer, stronger 7.2 mg dose, which in a separate study helped patients lose an average of about 47 pounds, roughly neck-and-neck with Zepbound (The Rundown). This came up on nearly every finance and biotech show: The Readout Loud, Motley Fool Hidden Gems Investing, and CNBC's Fast Money all read it the same way: as a sign of how much the balance of power has shifted. Over the last 12 months, Lilly's stock is up about 50% while Novo's is down about 24% (The Rundown), and Lilly is now estimated to hold roughly 60% of the market, with sales still growing while Novo's are expected to decline this year (Motley Fool Hidden Gems Investing).

The bigger takeaway from the Motley Fool hosts: obesity drugs are turning into a normal consumer product, and pricing is coming down. As one host put it, this space has gone "from, OK, we're going to be able to charge three thousand dollars a month for these treatments to this is kind of just a consumer product at this point" (Motley Fool Hidden Gems Investing). With margins getting squeezed, volume and market share matter more than ever, which is why, in their read, Novo is fighting so hard.

Theme 2: The next generation of obesity drugs is coming, and it's stronger. Several shows looked past the current fight to what's in the pipeline. Lilly's retatrutide, a "triple-G" drug that hits three gut hormones at once (GLP-1, glucagon, and GIP), is the one everyone is watching. On Bloomberg Intelligence, Bloomberg's Madison Muller reported that Lilly gave a fresh update on when it plans to file retatrutide for approval, with weight loss reaching up to about 30% and a regulatory filing targeted for early 2027. The health podcast Hard Drugs laid out the comparison cleanly: at top doses, retatrutide showed about a 28% weight reduction, versus roughly 21% for tirzepatide (Mounjaro/Zepbound) and about 15% for semaglutide (Ozempic/Wegovy). That episode also flagged the diabetes-prevention angle, in the SURMOUNT-1 trial, tirzepatide cut progression to diabetes by 94% over three years (2% of patients progressed versus 18% on placebo). The Readout Loud made the point that these more powerful drugs raise the stakes on safety and monitoring, more on that below.

Theme 3: The oral (pill) obesity race is starting to matter. Morning Brew Daily shared a striking early stat on the pill versions of these drugs: Novo's oral Wegovy had generated about 153,000 US prescriptions as of July 3rd, versus under 20,000 for Lilly's competing pill, giving Novo roughly an 89% share of the early oral market. It's a rare recent data point where Novo is clearly ahead, and it hints that the injectable-vs-pill battle may not map neatly onto today's injectable leaderboard.

Theme 4: "Biotech is back" as a market narrative. On the finance side, the mood around drug stocks was noticeably upbeat. CNBC's Power Lunch ran a segment literally titled "Biotech's Big Comeback," noting the two main biotech ETFs have surged over the past year, and hosting BMO's head of healthcare research, Evan Siegerman, to talk stock picks ahead of earnings season (which kicks off with Bristol-Myers Squibb). On The Macro Dirt Podcast, veteran trader Guy Adami said he expects a second-half wave of biotech mergers and acquisitions. The comeback theme isn't universal, though, a fund manager on MoneyWeek Talks discussed where to find "healthy profits" more selectively, and Citeline devoted an episode to whether European biotech can stay competitive given financing and policy headwinds.

Theme 5: The "picks and shovels" suppliers had a rough week, led by Danaher. The companies that sell equipment and services to drugmakers (often called "life sciences tools") got hit. Danaher (DHR) had "its worst day since 2001" after earnings (Fast Money). The problem wasn't the headline numbers, it was that "bioprocessing" (the business of manufacturing new drugs) got its recovery pushed out again, now to early 2027. Intuitive Surgical (ISRG), the maker of the Da Vinci surgical robot, also fell sharply on slowing procedure growth (The Canadian Investor). Both stories are less about a broken business and more about high-priced stocks getting punished for anything short of perfect (details in the stock section below).

Theme 6: Gene editing is attracting real, multi-billion-dollar money. Citeline interviewed ElevateBio's Chief Scientific Officer Amy Pooler about the company's "bet on every gene-editing tool at once" strategy, and used two recent Lilly deals to show how seriously big pharma is taking the field: Lilly signed a $1.1 billion deal with Seamless Therapeutics for recombinase-based gene therapies, then followed with a $2.2 billion partnership with ProFluent for AI-designed recombinases. The idea driving these deals is "programmable insertion", dropping a healthy copy of a gene into the genome rather than fixing one mutation at a time, which could treat far more patients (Pooler used the inherited disorder PKU as an example).

Theme 7: AI in drug discovery: real progress, but no finished product yet. A cluster of shows dug into how much AI is actually changing drug discovery. The recurring, honest conclusion: AI is genuinely good at optimization (finding the best conditions among known options) but still early at true discovery, and there is still no fully "AI-discovered" drug approved and on the market (Digital Pathology Podcast). More on the debate below.

Theme 8: FDA turns up the enforcement heat, especially on compounded GLP-1s and telehealth. FDA Watch laid out a striking picture of 2026 as a year of "unprecedented" enforcement: since September 2025, the FDA has issued over 100 warning letters to companies compounding and marketing GLP-1s, and the Department of Justice reached a criminal resolution with Alibaba earlier this month over online sales of regulated products. Separately, the FDA's new "PreCheck" pilot, which moves factory inspections earlier in the approval process, chose Solaris as one of just seven companies from 80 applicants (Off Script).

Theme 9: Cancer data from ASCO 2026, plus deal-making beyond obesity. A very large cluster of clinical oncology podcasts recapped data from this year's ASCO meeting (lung, breast, myeloma, ovarian, and endometrial cancers). These shows are aimed at doctors rather than investors, so the takeaway for a portfolio is more about which drug classes and mechanisms are winning than about specific stock calls, antibody-drug conjugates (ADCs) and bispecific antibodies keep showing up as the momentum areas. On the deal side, Lilly's roughly $2.8 billion acquisition of Atai Beckley (for an intranasal psychedelic in Phase 3 for treatment-resistant depression) surfaced across BioCentury This Week, The Dales Report | Trade to Black, and Health:Further, and Merck's newly FDA-approved oral cholesterol pill (a PCSK9 inhibitor branded Lipfendra, with 55–59% LDL reductions at about $10.50 a day) was highlighted on Science News Daily.

2. Active Debates

Debate 1: Is Novo's lawsuit a smart move or an act of desperation? This was the week's liveliest two-sided discussion. The "desperation" camp was loud. On The Rundown, the host called it "sour grapes… Novo Nordisk is just frustrated that they fumbled the lead so bad, and now they're hitting the lawsuit button in hopes of slowing down Lilly." On Fast Money, the analyst agreed it "seems a little bit desperate," adding that everyone already knows tirzepatide is stronger than semaglutide, so the exact dosing in the ads is "sort of meaningless, the doctors know and the patients know." But the Motley Fool hosts offered a more sympathetic read: both sides are "technically right" (Lilly is quoting real trial results, just older ones; Novo does have a newer pill that does better in updated trials), and even if Novo loses in court, it has already won something, it got everyone talking about the fact that its newer product is better than the old one. Their verdict: with a "gold mine" this big, "why not?"

Debate 2: Is AI actually revolutionizing drug discovery, or is it hype? On the Digital Pathology Podcast, Thibault Geoui drew a careful line between two things AI is asked to do. For optimization problems, like finding the right recipe to grow a cell line or crystallize a protein, AI and automation are clearly better than humans and "can and should be autonomous." But for true discovery, where "even expressing the question is difficult," humans are still essential. He also punctured a common claim: most so-called "AI-developed drugs" already on the market are actually repurposed drugs (old drugs aimed at a new disease), which he argues doesn't really count. His own bar for a genuine AI-developed drug, AI meaningfully involved in target-finding, molecule design, and trial design, has been cleared in the pipeline (he pointed to Silicon Medicine compressing years of work into months) but not yet in an approved, marketed product. He also cited a sobering backdrop: a famous Amgen analysis and later surveys found that roughly 60–70% of life-science experiments are not reproducible, which is exactly the mess AI is being asked to clean up. On the optimistic end, Ground Truths highlighted Stanford's "Biomni" and Anthropic's "Claude Science" as landmark agentic-AI tools for biology (able to draw on 150+ specialized tools, thousands of publications, and over a billion data points), while cautioning the field is still early. Data in Biotech featured Woody Sherman (formerly of Schrödinger and Silicon Therapeutics) arguing that large language models are the wrong tool for molecules, you need "physical AI" built on the quantum-mechanical properties of atoms, an approach he says took a STING-agonist drug from concept to clinic in three years. And Latent Space hosted Xaira's team on their "virtual cell" model, X-Cell, arguing that the quality of the underlying experimental data (genome-wide CRISPR "perturbation" screens) matters more than model size.

Debate 3: Are these expensive medtech/tools stocks now cheap enough to buy? For Danaher, the Fast Money desk openly debated whether five years of underperformance means the bad news is finally priced in ("Do we cover this if we're short? Do we go long?"). Mizuho's Jared Holz leaned toward buying the weakness and floated Repligen (down nearly 10% on the day) as an arguably better way to play a bioproduction rebound, since Danaher's weakness may be company-specific rather than industry-wide. For Intuitive Surgical, The Canadian Investor hosts made the case that the stock is now "pretty much the cheapest it's been" in 7–8 years even as revenue grew 19%, but acknowledged the market is unforgiving of any deceleration in a still-pricey, "not obviously AI" stock.

Debate 4: How much monitoring do GLP-1 patients really need? The Readout Loud hosted a genuinely two-sided discussion prompted by a STAT investigation into telehealth prescriber LifeMD (which denies the allegations). The "what's the harm" side notes most people view these drugs as safe. The counter: without careful monitoring, rapid weight loss can trigger eating disorders, gallstones, pancreatitis, and malnutrition, and the reporter described asynchronous "fill-out-a-form" refills, sometimes at inappropriately high restart doses. The investment-relevant tension: the more the market pushes toward frictionless, telehealth-driven prescribing to chase volume, the more regulatory and headline risk builds, right as more potent drugs like retatrutide arrive.

Debate 5: Is gene editing at a real inflection point, or is there still hype to burn off? Asked directly on Citeline whether big pharma's conviction is justified, ElevateBio's Amy Pooler answered "probably a little bit of both", the promise of treating whole patient populations (rather than single mutations) is real and is what's driving the "big bucks," but disease biology remains genuinely uncertain even when the editing tool works as designed.

3. Stock-by-Stock: Bull vs. Bear (as argued on the podcasts)

Eli Lilly (LLY)

  • Bull: Clear market leader in obesity at ~60% share, with sales still growing while rivals shrink; stock up ~50% over 12 months; the strongest next-gen pipeline (retatrutide, up to ~30% weight loss, filing targeted early 2027); and it is spending aggressively on the future via gene-editing deals ($1.1B Seamless, $2.2B ProFluent) and a ~$2.8B move into psychedelics (Atai Beckley). BMO's Evan Siegerman said flatly he prefers "Lilly over Novo" (Power Lunch).
  • Bear: The whole category is de-rating from premium pricing toward "consumer product" economics, squeezing margins; Novo's lawsuit and FDA scrutiny of aggressive GLP-1 marketing add legal/headline risk; and Novo is actually winning the early oral-pill race (~89% share) (Motley Fool; Morning Brew Daily).

Novo Nordisk (NVO)

  • Bull: Best brand recognition (Ozempic, Wegovy); a competitive newer 7.2 mg dose (~47 lbs lost) and a clear lead in oral GLP-1 pills; and, per BMO, a possible guidance upgrade at its August 5 earnings that "might help sentiment," with the rest of the business currently "valued effectively… at nil" (Power Lunch; Fast Money).
  • Bear: Lost its lead to Lilly; stock down ~24% over 12 months; sales expected to decline this year; and the lawsuit is widely read as a sign of "desperation" rather than strength (The Rundown; Motley Fool).

Merck (MRK)

  • Bull: BMO's Siegerman has a Buy and a $142 price target, citing "real credibility for management" in how they are handling the looming loss of patent protection on Keytruda, their ~$30 billion cancer drug, at the end of the decade, via acquisitions and internal development. He prefers Merck over Bristol-Myers Squibb. A new FDA approval this week (oral PCSK9 pill Lipfendra, 55–59% LDL reduction) adds a fresh product (Power Lunch; Science News Daily).
  • Bear: The Keytruda patent cliff is enormous, and management still has to "replace" a large chunk of $30B in sales, execution risk is real (Power Lunch).

AbbVie (ABBV)

  • Bull: Siegerman rates it Outperform with a $300 target, points to its just-announced deal for Apogee (expanding its immunology franchise), leadership in inflammatory disease with Skyrizi and Rinvoq, and more data due later this year (Power Lunch).
  • Bear: Investors worry about competition from Johnson & Johnson's Tremfya and Icotrokinra, though BMO says it isn't yet showing up in prescription data (Power Lunch).

Bristol-Myers Squibb (BMY)

  • Bull/Bear: Reports first among the majors "next week," so it's the early read on the group; BMO explicitly prefers Merck over Bristol, making it more of a relative laggard within a hot sector (Power Lunch).

Danaher (DHR)

  • Bull: Earnings and revenue both beat; equipment demand was "very strong"; the stock has lagged for five years, so a lot of bad news may be priced in; Mizuho's Jared Holz leaned toward buying the weakness (Fast Money).
  • Bear: Management cut the bioprocessing outlook and pushed the expected recovery out to early 2027, driving the worst day since 2001; a separate analyst on InvestTalk flagged ~5.5% revenue growth (a beat) but 22x forward earnings, margin compression, and segment growth below expectations, recommending patience despite solid fundamentals.

Repligen (RGEN), Called out by Mizuho as possibly the better way to play a bioproduction rebound; it fell nearly 10% in sympathy with Danaher, but the read is that Danaher's problem may be company-specific, not industry-wide (Fast Money).

Bruker (BRKR) and Revvity (RVTY), Both rose on Danaher's results, since Danaher's strength in equipment was a positive read-through for the wider peer group (Fast Money).

Intuitive Surgical (ISRG)

  • Bull: Revenue up 19% and earnings up 23%; the stock is trading around 31x forward earnings and ~27x forward free cash flow, roughly its cheapest in 7–8 years; the razor-and-blades model (sell the robot, then sell recurring instruments and accessories) remains intact; and management is layering in AI/software tools built on 20 million cumulative procedures and 100,000+ trained surgeons (The Canadian Investor; Medtech Talk).
  • Bear: Procedure growth slowed to 15% (from 16% the prior quarter), and full-year guidance of ~14.5% implies the next two quarters could dip toward ~13% or even 12.5%; the 23% earnings gain was flattered by a one-time $36 million tariff reimbursement; and for a premium-priced stock, "in-range" guidance simply isn't good enough, the market wants beats (The Canadian Investor).

Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), Summit Therapeutics (SMMT), Insmed (INSM), Guy Adami on The Macro Dirt Podcast named all four as potential second-half M&A targets. He's "pretty convinced" Structure Therapeutics (which spiked ~100% in a day back in December and has since round-tripped the entire move) gets acquired by a big pharma buyer, and he called Insmed, which ran from about $100 to $210 and then gave it all back, "potentially the next Genentech." (Note: this is one trader's conviction, not a data-backed call.)

Procept BioRobotics (PRCT), On Wall Street Wildlife, the bull case: the stock trades near all-time lows despite real fundamental progress, a US medical-society guideline upgrade for its heat-free "aquablation" treatment for enlarged prostates, a second FDA approval in prostate cancer, and completed trial enrollment. The bear/why-it's-cheap case: a new CEO's pivot to selling fewer machines at higher prices to better hospitals has flattened procedure counts near ~12,000 per quarter, which the market dislikes.

Amgen (AMGN), Featured on Becker's Healthcare sponsoring an "Osteoporosis Action Network" aiming to prevent 3 million fractures by 2033, a disease-awareness and market-development effort rather than a pipeline or stock discussion.

Fractyl Health, On DeviceTalks, CEO Harith Rajagopalan pitched its Revita procedure as a device-based "off-ramp" for the "weight-maintenance problem", the tendency of patients to regain weight after stopping GLP-1s. A niche but interesting attempt to build a business around the obesity-drug wave rather than competing with it.

Sparrow Pharmaceuticals, On Biotech 2050, CEO Robert Cuddy positioned its cortisol-suppressing drug as complementary to GLP-1s, presenting Endocrine Society data on excess cortisol in patients with hypertension and hard-to-control diabetes.

4. Notable Quotes

  • On Novo suing Lilly: "To me, this just seems like Novo Nordisk having some sour grapes and trying to do whatever they can to fight back against Eli Lilly… Eli Lilly stock has gone up 50% in the last 12 months, while Novo Nordisk has lost 24%.", host, The Rundown

  • On both sides being right: "Reading the suit seems like both sides are technically right here. Lilly is accurately giving the results of comparison trials. But oopsie, conveniently forgetting to mention that the trials are a bit dated now, that there's an updated Novo pill that does better.", host, Motley Fool Hidden Gems Investing

  • On obesity drugs becoming a commodity: "This space has gone from, OK, we're going to be able to charge three thousand dollars a month for these treatments to this is kind of just a consumer product at this point.", host, Motley Fool Hidden Gems Investing

  • On Danaher's guide-down: "I think the street wanted to see improvement in bioprocessing… They actually took that number down a bit… it seems like that tailwind is probably not going to take place until maybe early 2027.", Jared Holz, Mizuho, on Fast Money

  • On playing the sell-off: "The one name that sort of stands out is Repligen… I think Repligen could be the way to actually play this. If you're bullish, big picture.", Jared Holz, Mizuho, on Fast Money

  • On Merck's patent cliff: "The momentum behind it is real credibility for management and how they're solving for the Keytruda [loss of exclusivity] at the end of the decade. This is their massive cancer drug, $30 billion in sales that they're going to have to replace.", Evan Siegerman, BMO, on Power Lunch

  • On AI's real strengths and limits: "There is something which is kind of an optimization and something which is discovery… [optimization] is really the type of thing where it can and should be autonomous… the complete discovery is still where the human involvement is very important.", Thibault Geoui, on Digital Pathology Podcast

  • On "AI drugs" being oversold: "There is no real AI developed drug that is marketed at the moment… if you look into the literature, you will see that there are maybe one or two drugs that are called AI developed drugs… but these are repurposed drugs.", Thibault Geoui, on Digital Pathology Podcast

  • On FDA's widening net: "Anyone who touches an FDA regulated product is no longer outside the enforcement perimeter.", Gabe Skana-Pieko, Arnold Golden Gregory, on FDA Watch

  • On GLP-1 safety with light monitoring: "As with any drug, in excess, these medications can be dangerous… if you're not carefully monitored, there's the risk of eating disorders, of losing too much weight too quickly, which can then lead to… pancreatitis, gallstones, malnutrition.", reporter, The Readout Loud

  • On the gene-editing wave: "Eli Lilly recently signed a $1.1 billion deal with Seamless Therapeutics for recombinase-based gene therapies, and followed that with a $2.2 billion partnership with ProFluent for AI-designed recombinases.", Citeline

5. Catalysts to Watch

  • Big pharma / biotech earnings season kicks off. Bristol-Myers Squibb reports "next week," the first of the majors (Power Lunch).

  • Novo Nordisk earnings on August 5. Watched closely for a possible guidance upgrade that BMO thinks could lift sentiment on a beaten-down stock (Fast Money; Power Lunch).

  • Lilly's retatrutide regulatory filing targeted for early 2027, the drug that could redefine the top end of the weight-loss market (up to ~30% weight loss) (Bloomberg Intelligence).

  • The Novo–Lilly lawsuit itself. No verdict yet; possible outcomes range from Lilly trimming its advertising or adjusting how it presents dosing, to a drawn-out fight, but several hosts think the marketing narrative already shifted regardless of the legal result (Motley Fool).

  • Danaher's bioprocessing recovery, now expected early 2027, the key swing factor for the tools group; watch peers (Repligen, Bruker, Revvity) for confirming or conflicting signals (Fast Money).

  • AbbVie: more Skyrizi/Rinvoq data due later this year, plus integration of the Apogee deal (Power Lunch).

  • Second-half biotech M&A. Guy Adami's watchlist of possible targets: Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), Summit (SMMT), and Insmed (INSM) (The Macro Dirt Podcast).

  • FDA policy threads: ongoing enforcement waves against GLP-1 compounders and telehealth platforms (FDA Watch); a US House panel proposal to ban clinical-trial data from China, Russia, Iran, and North Korea in FDA applications (Note to File); the FDA's PreCheck manufacturing pilot (Off Script); and, on the HHS side, Paging America reported RFK Jr.'s proposal to spend ~$5 billion (about 10% of NIH's annual budget) studying vaccine-autism links was dropped after NIH director Bhattacharya and White House officials opposed it.